Brief: Achilles Therapeutics Presents Positive Data at ESMO I-O Congress 2021 on High-Dose Manufacturing Process for Precision T Cell Therapies Targeting Clonal Neoantigens
09/12/2021 12:40
Dec 9 (Reuters) - Achilles Therapeutics PLC 698y.F :
* ACHILLES THERAPEUTICS PRESENTS POSITIVE DATA AT ESMO I-O
CONGRESS 2021 ON HIGH-DOSE MANUFACTURING PROCESS FOR PRECISION T
CELL THERAPIES TARGETING CLONAL NEOANTIGENS
Source text for Eikon: ID:nGNX9gw2jd
Further company coverage: 698y.F
((Reuters.Briefs@thomsonreuters.com;;))
Recent news on Achilles Therapeutics
See all newsBrief: Achilles Therapeutics Announces Sale Of Technology Assets To Astrazeneca
Brief: Achilles Therapeutics Receives Approval To Transfer To Nasdaq Capital Market
Achilles gains on plans to explore strategic options
Brief: Achilles Therapeutics To Discontinue Development Of TIL-Based cNET Therapy
Brief: Achilles Therapeutics Receives Nasdaq Deficiency Notice Regarding Minimum Bid Price Requirement